CapEdge
Loading...
Advanced
What's new? Log in Free sign up
  • Home
  • Sectors & IndustriesSectors
  • Earnings
  • IPOs
  • SPACs
  • Transcripts
  • Insider
  • Institutional
  • Crypto
  • Screeners
  • Reddit
  • Splits
  • FRTX Dashboard
  • Financials
  • Filings
  • Transcripts
  • ETFs
  • Insider
  • Institutional
  • Shorts
  • News
  • Patents
  • Reddit
  • 8-K Filing

Fresh Tracks Therapeutics (FRTX) 8-KBrickell Biotech Reports Second Quarter 2021

Filed: 12 Aug 21, 4:03pm
Free signup for more
  • Track your favorite companies
  • Receive email alerts for new filings
  • Personalized dashboard of news and more
  • Access all data and search results
Sign up for free
Search this filing
?
Pre-defined:
Table of contents
    Filing tables
    Export all tables to Excel
    Filing exhibits
    SEC
    • 8-K Current report
    • 99.1 Brickell Biotech Reports Second Quarter 2021
    • Download Excel data file
    • View Excel data file
    Related financial report
    • 2021 Q2 Quarterly report
    FRTX similar filings
    • 7 Oct 21 Regulation FD Disclosure
    • 7 Oct 21 Regulation FD Disclosure
    • 1 Sep 21 Entry into a Material Definitive Agreement
    • 12 Aug 21 Brickell Biotech Reports Second Quarter 2021
    • 22 Jul 21 Brickell Biotech Announces $5.0 Million Bought Deal Offering of Common Stock
    • 17 Jun 21 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
    • 13 May 21 Brickell Biotech Reports First Quarter 2021
    Filing view
    Share this filing

     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM 8-K 


    CURRENT REPORT
    Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934
    Date of report (Date of earliest event reported) August 12, 2021
    bbi-20210812_g1.jpg
    BRICKELL BIOTECH, INC.
    (Exact name of Registrant as specified in its charter)
    Delaware000-2108893-0948554
    (State or Other Jurisdiction
    of Incorporation)
    (Commission File
    Number)
    (IRS Employer
    Identification No.)

    5777 Central Avenue
    Suite 102
    Boulder, CO 80301
    (Address of Principal Executive Offices) (Zip Code)
    Registrant’s telephone number, including area code: (720) 505-4755
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading
    Symbol(s)
    Name of each exchange
    on which registered
    Common stock, par value $0.01 per shareBBIThe Nasdaq Stock Market LLC
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐




    Item 2.02. Results of Operations and Financial Condition.
    On August 12, 2021, Brickell Biotech, Inc. issued a press release reporting, among other things, its financial results for the three and six months ended June 30, 2021. A copy of the press release is attached as Exhibit 99.1 to this Current Report.
    The information in this Item 2.02, and Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.
    Item 9.01. Financial Statements and Exhibits.
    (d) Exhibits.
    99.1    Press release issued by Brickell Biotech, Inc. on August 12, 2021
    104 Cover Page Interactive Data File (embedded within the Inline XBRL document)



    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
    Date: August 12, 2021Brickell Biotech, Inc.
    By:/s/ Robert B. Brown
    Name:Robert B. Brown
    Title:Chief Executive Officer


    Finsight
    Resources
    • Knowledgebase
    • Log In
    • Register
    Company
    • About
    • Contact
    • Solutions
    Products
    • Deal Roadshow
    • DealVDR
    • Evercall
    • Finsight.com
    CapEdge
    • Earnings Calendar
    • Earnings Transcripts
    • EDGAR Filing Screener
    • IPO Calendar
    • Compliance
    • Privacy
    • Security
    • Terms
    AngelList LinkedIn